Revolution Medicines and Moderna prove that high-risk bets on undruggable targets can finally work - here's what it means for biotech investors and pharma execs.

Revolution Medicines' new pancreatic cancer treatment Rasonque carries a record annual cost, highlighting a decade-long trend of soaring oncology prices.